Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Haemonetics said it achieved its prior long-range plan targets, including double-digit revenue growth ex-CSL, high-teens EPS and earnings growth, a 660 bps improvement in operating margin to the mid-20s, and nearly $700M of free cash flow. Management framed the result as evidence the company has moved successfully past the CSL transition and is now setting a new guide. The update is constructive for fundamentals, but it is primarily a strategy and performance recap rather than a new catalyst.

Analysis

HAE’s setup looks less like a cyclical re-rating and more like a de-risking of a previously complex story: once a company proves it can absorb a major revenue headwind and still expand margins, the market typically starts valuing the remaining core at a higher multiple. The second-order effect is that “execution beta” should compress; investors who were paying for turnaround optionality may now pivot to quality and cash conversion, which is supportive for the stock even if near-term growth decelerates. That also matters competitively: suppliers and channel partners will likely face a more disciplined customer that is now optimizing for profitability, not just top-line recovery.

The key question is whether the next leg is driven by further margin expansion or by capital allocation. If the core franchise is already in the mid-20s operating margin range, incremental upside becomes more about free cash flow durability, buybacks, and bolt-on tuck-ins than about another large operational step-up. That changes the valuation math: the stock can keep grinding higher over months, but the easiest gains should come on evidence that cash flow is being returned aggressively rather than reinvested into low-ROIC growth.

The main risk is that the market extrapolates the prior cadence too linearly. In medtech, post-disruption normalization often creates a 1-2 quarter air pocket where reported growth looks less exciting even as underlying profitability remains healthy; that’s where multiples can compress if investors are expecting a straight-line beat-and-raise. A sharper-than-expected slowdown in procedure volumes or any pricing pressure from hospital purchasing groups would matter more now because the story has shifted from recovery to sustainment.

Key Decisions for Investors

• Long HAE on a 3-6 month horizon into any post-conference pullback; thesis is multiple expansion from proven execution and cash flow conversion, with downside limited if margins hold in the mid-20s.
• Use a call spread in HAE (3-9 months) rather than outright stock if positioning is already crowded; captures rerating upside while limiting drawdown if the market demands a digestion quarter.
• Pair HAE long vs. a lower-quality medtech peer with weaker margin conversion and more leverage; the trade should work over 1-2 quarters if investors rotate toward self-funding compounders.
• Trim/add rule: if HAE trades as if the market is assuming another step-function beat, reduce exposure after the next earnings print unless management explicitly raises capital return targets.
• If procedure-volume indicators soften, hedge HAE with a broad healthcare ETF short over 1-2 months; the stock’s new valuation depends more on sustainment than on additional turnaround torque.